[an error occurred while processing this directive] | [an error occurred while processing this directive]
Influence of survival in primary tumor volume for stage IV non-small cell lung cancer on survival-re-analysis of phase II multicenter prospective clinical findings
Luo Lan,Ouyang Weiwei,Su Shengfa,Ma Zhu,Li Qingsong,Yang Wengang,Fu Shimei,Lu Bing
Department of Oncology,Guizhou Cancer Hospital,Affiliated Hospital of Guizhou Medical University,Guiyang 550004,China
AbstractObjective To investigate the effect of primary tumor volume on the survival in the three-dimensional radiotherapy of primary tumors of stage Ⅳ non-small cell lung cancer (NSCLC). Methods Clinical data of 428 patients in a multicenter prospective clinical study from December 2002 to January 2017 were reanalyzed, and 423 of them were subject to survival analyses. Platinum-based doublet chemotherapy was adopted. The median number of chemotherapy cycle was 4, and the critical value of planning target volume (PTV) of primary tumors was 63 Gy. The critical value of gross tumor volume (GTV) of primary tumors was 150 cm3. Results Single factor Cox regression analysis demonstrated that female, KPS score, single organ metastasis,N0-N1 staging, adenocarcinoma, radiotherapy dose ≥63 Gy,4-6 cycles of chemotherapy, recent effectiveness, post-treatment progress in taking targeted drugs and GTV<150 cm3 were good prognostic factors for the patients with stage Ⅳ NSCLC (all P<0.05). According to the stratified analysis of different radiotherapy regimes, for the stage Ⅳ NSCLC patients with a GTV ≥150 cm3,the survival rate of the primary tumor radiotherapy dose ≥63 Gy on the basis of systemic chemotherapy was significantly better than that of the primary tumor radiotherapy dose <63 Gy (P<0.05). Conclusions Stage Ⅳ NSCLC patients with GTV≥150 cm3 in 4-6 cycles of chemotherapies combined with primary tumor radiotherapy dose ≥63 Gy and GTV<150 cm3 in 1-3 cycles of chemotherapies combined with primary tumor radiotherapy dose ≥63 Gy may prolong the overall survival of patients with stage Ⅳ NSCLC.
Luo Lan,Ouyang Weiwei,Su Shengfa et al. Influence of survival in primary tumor volume for stage IV non-small cell lung cancer on survival-re-analysis of phase II multicenter prospective clinical findings[J]. Chinese Journal of Radiation Oncology, 2019, 28(9): 660-664.
Luo Lan,Ouyang Weiwei,Su Shengfa et al. Influence of survival in primary tumor volume for stage IV non-small cell lung cancer on survival-re-analysis of phase II multicenter prospective clinical findings[J]. Chinese Journal of Radiation Oncology, 2019, 28(9): 660-664.
[1] Jemal A,Bray F,Center MM,et al. Global cancer statistics[J]. CA Cancer J Clin,2011,61(1):69-90. DOI:10.3322/caac.20107. [2] Siegel RL,Miller KD,Jemal A. Cancer statistics,2019[J]. CA Cancer J Clin,2019,69(1):7-34. DOI:10.3322/caac.21551. [3] Su SF,Hu YX,Ouyang WW,et al. The survival outcomes and prognosis of stage Ⅳ non-small-cell lung cancer treated with thoracic three-dimensional radiotherapy combined with chemotherapy[J]. Radiat Oncol,2014,9(1):290-296. DOI:10.1186/s13014-014-0290-7. [4] Li D,Zhu X,Wang H,et al. Should aggressⅣ e thoracic therapy be performed in patients with synchronous oligometastatic non-small cell lung cancer? A meta-analysis[J]. J Thorac Dis,2017,9(2):310-317. DOI:10.21037/jtd.2017.02.21. [5] Schiller JH,Harrington D,Belani CP,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med,2002,346(1):92-98. DOI:10.1056/NEJMoa011954. [6] Gronberg BH,Bremnes RM,Flotten O,et al. Phase Ⅲ study by the Norwegian lung cancer study group:pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer[J]. J Clin Oncol,2009,27(19):3217-3224. DOI:10.1200/JCO.2008.20.9114. [7] Higginson DS,Chen RC,Tracton G,et al. The impact of local and regional disease extent on overall survival in patients with advanced stage ⅢB/Ⅳ non-small cell lung carcinoma[J]. Int J Radiat Oncol Biol Phys,2012,84(3):e385-392. DOI:10.1016/j.ijrobp.2012.04.045. [8] Mehta N,Mauer AM,Hellman S,et al. Analysis of further disease progression in metastatic non-small cell lung cancer:implications for locoregional treatment[J]. Int J Oncol,2004,25(6):1677-1683. [9] Tian J,Shi RH,Jian T,et al. Influential factor for the survival after radiotherapy for brain metastases from the pulmonary tumor in the 45 patients[J]. China Oncology,2006,16(2):310-312. [10] Fairchild A,Harris K,Barnes E,et al. Palliative thoracic radiotherapy for lung cancer:a systematic review[J]. J Clin Oncol,2008,26(24):4001-4011. DOI:10.1200/JCO.2007.15.3312. [11] Ouyang WW,Su SF,Hu YX,et al. Radiation dose and survival of patients with stage Ⅳ non-small cell lung cancer undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy:reanalysis of the findings of a single-center prospective study[J]. BMC Cancer,2014,14(1):491-498. DOI:10.1186/1471-2407-14-491. [12] Su SF,Li T,Lu B,et al. Three-Dimensional radiation therapy to the primary tumor with concurrent chemotherapy in patients with stage Ⅳ non-small cell lung cancer:results of a multicenter phase 2 study from PPRA-RTOG,China[J]. Int J Radiat Oncol Biol Phys,2015,93(4):769-777. DOI:10.1016/j.ijrobp.2015.08.012. [13] Zhang R,Li P,Qin L,et al. Radiotherapy improves the survival of patients with stage Ⅳ NSCLC:A propensity score matched analysis of the SEER database[J]. Cancer Med,2018,00:1-12. DOI:10.1002/cam4.1776. [14] Su SF,Hu YX,Ouyang WW, et al. Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage Ⅳ non-small cell lung cancer?:Secondary analysis of two prospective studies[J]. BMC Cancer,2016,16(1):908-917. DOI:10.1186/s12885-016-2952-3.
2019, Vol. 28 
